Trade

with

Peregrine Pharmaceuticals Inc
(NASDAQ: PPHM)
AdChoices
1.49
+0.05
+3.47%
After Hours :
1.55
+0.06
+4.03%

Open

1.45

Previous Close

1.44

Volume (Avg)

1.35M (1.09M)

Day's Range

1.44-1.52

52Wk Range

1.16-3.18

Market Cap.

267.46M

Dividend Rate ( Yield )

-

Beta

1.31

Shares Outstanding

179.51M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 22.40M

    • Net Income

    • -35.36M

    • Market Cap.

    • 267.46M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -182.34

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.31

    • Forward P/E

    • -4.51

    • Price/Sales

    • 10.85

    • Price/Book Value

    • 4.08

    • Price/Cash flow

    • -7.99

      • EBITDA

      • -34.37M

      • Return on Capital %

      • -60.06

      • Return on Equity %

      • -86.25

      • Return on Assets %

      • -60.06

      • Book Value/Share

      • 0.37

      • Shares Outstanding

      • 179.51M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 5.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.31

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 17.20

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 4.30

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 39.58

            • 82.75

            • Pre-Tax Margin

            • -176.19

            • 39.38

            • Net Profit Margin

            • -182.34

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 46.30

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -175.70

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 3.86

              • 2.92

              • Quick Ratio

              • 3.53

              • 2.35

              • Interest Coverage

              • -10,221.75

              • 38.02

              • Leverage Ratio

              • 1.34

              • 2.21

              • Book Value/Share

              • 0.37

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -6.19

                • 188.68

                • P/E Ratio 5-Year High

                • -21.97

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.56

                • 124.82

                • Price/Sales Ratio

                • 11.29

                • 8.72

                • Price/Book Value

                • 4.24

                • 7.95

                • Price/Cash Flow Ratio

                • -7.99

                • 45.45

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -86.25

                    (-207.00)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -60.06

                    (-85.90)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -86.24

                    (-180.20)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 2.40

                  • 1.48

                  • Asset Turnover

                  • 0.33

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -35.71M
                  Operating Margin
                  -159.39
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -7.99
                  Ownership

                  Institutional Ownership

                  14.69%

                  Top 10 Institutions

                  10.60%

                  Mutual Fund Ownership

                  9.20%

                  Float

                  99.42%

                  5% / Insider Ownership

                  0.50%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    2,838,489

                  • 0.00

                  • 1.58

                  • iShares Russell 2000 (AU)

                  •  

                    2,757,473

                  • -1.01

                  • 1.68

                  • Vanguard Extended Market Index Fund

                  •  

                    1,657,920

                  • 1.04

                  • 0.92

                  • iShares Russell 2000 Growth

                  •  

                    1,231,306

                  • 0.77

                  • 0.75

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    579,602

                  • 0.00

                  • 0.32

                  • CREF Stock

                  •  

                    559,059

                  • 1.64

                  • 0.31

                  • iShares Micro-Cap

                  •  

                    477,280

                  • 0.00

                  • 0.29

                  • BlackRock Small Cap Growth Equity Port

                  •  

                    437,447

                  • 0.00

                  • 0.24

                  • QS Batterymarch US Sm Cp Eq Ptf

                  •  

                    391,300

                  • 0.00

                  • 0.22

                  • Schroder Global Healthcare Fund

                  •  

                    367,788

                  • 0.00

                  • 0.21

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • BlackRock Fund Advisors

                  •  

                    5,794,155

                  • +4.88%

                  • 3.24

                  • Vanguard Group, Inc.

                  •  

                    4,857,865

                  • +1.97%

                  • 2.72

                  • State Street Corp

                  •  

                    2,152,610

                  • -0.06%

                  • 1.20

                  • Northern Trust Investments, N.A.

                  •  

                    1,931,051

                  • -6.93%

                  • 1.08

                  • Geode Capital Management, LLC

                  •  

                    981,683

                  • +21.27%

                  • 0.55

                  • TIAA-CREF Investment Management LLC

                  •  

                    767,332

                  • +31.43%

                  • 0.43

                  • BlackRock Advisors LLC

                  •  

                    669,732

                  • -2.16%

                  • 0.37

                  • BNY Mellon Asset Management Ltd.

                  •  

                    662,038

                  • +7.79%

                  • 0.37

                  • QS Batterymarch Financial Management Inc.

                  •  

                    614,300

                  • -8.57%

                  • 0.34

                  • Nomura Holdings Inc

                  •  

                    540,333

                  • -0.43%

                  • 0.30

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Peregrine Pharmaceuticals Inc was originally incorporated in California in June 1981 and reincorporated in the State of Delaware on September 25, 1996. The Company is a biopharmaceutical company developing monoclonal antibodies for t...morehe treatment and diagnosis of cancer. It is advancing its two oncology programs with its product candidates, bavituximab and Cotara, for the treatment of various cancers. In addition, the Company is advancing its main imaging agent, 124I-PGN650, into clinical development for the imaging of multiple solid tumor types. The Company’s pipeline of novel investigational monoclonal antibodies is based on two first-in-class technology platforms, including PS-targeting antibodies and DNA/histone-targeting antibodies. Bavituximab is its main therapeutic PS-targeting antibody, whic...moreh has demonstrated broad therapeutic potential and represents a new approach to treating cancer. PGN650 is its PS-targeting imaging agent that represents a potential new approach to imaging cancer. PS is a immunosuppressive molecule usually located inside the membrane surface of healthy cells, but ‘flips’ and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments and for the imaging of multiple solid tumor types. Under its imaging program, in April 2012, the Company filed an exploratory Investigational New Drug (‘IND’) application with the FDA to advance its main imaging agent PGN650 into clinical development for the imaging of multiple solid tumor types. Regulation by governmental authorities in the U.S. and other countries is a significant factor in its ongoing research and development activities and in the production of its products under development. The Company’s products and its research and development activities are subject to extensive governmental regulation in the U.S., including the Federal Food, Drug, and Cosmetic Act.lessless

                  Key People

                  Mr. Steven W. King

                  CEO/Director/President

                  Mr. Carlton M. Johnson, Jr

                  Chairman of the Board/Director

                  Mr. Paul J. Lytle

                  CFO/Chief Accounting Officer

                  Dr. Shelley P.M. Fussey,PhD

                  Vice President, Divisional

                  Mr. Joseph S. Shan

                  Vice President, Divisional

                  • Peregrine Pharmaceuticals Inc

                  • 14282 Franklin Avenue

                  • Tustin, CA 92780

                  • USA.Map

                  • Phone: +1 714 508-6000

                  • Fax: +1 714 838-5817

                  • peregrineinc.com

                  Incorporated

                  1981

                  Employees

                  184

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: